Business Context and Reporting Period
This Form 8-K filing by Tempest Therapeutics, Inc. (TPST) covers the event date of October 26, 2023. The company is a Delaware corporation headquartered in Brisbane, California, with common stock listed on The Nasdaq Stock Market LLC.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on regulatory compliance status rather than financial performance.
Material Changes
The primary material event reported is the Company's receipt of formal notification from Nasdaq confirming it has regained compliance with Listing Rule 5450(a)(1). This rule mandates that listed companies maintain a minimum closing bid price of $1.00 per share.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies beyond the resolution of the specific listing deficiency regarding the minimum bid price.
Investor Verification Checklist
- Verify the current trading price of TPST to ensure continued compliance with the $1.00 minimum bid price requirement.
- Confirm the date of the Nasdaq notification (October 26, 2023) against the company's stock price history.
- Review subsequent filings to ensure no new delisting notices have been issued.